Abstract
Objective
The purpose of this study was to assess the potential role of 18F-fluoride PET/CT over dual-phase bone scintigraphy (DBS) in evaluation and management of lesions causing foot and ankle pain.
Methods
99mTc-HDP DBS and 18F-fluoride PET/CT were performed in consecutive patients who visited rehabilitation department due to foot or ankle pain. Focal painful lesions in fore, mid, and hindfoot or ankle, and diffuse pain in foot were evaluated on DBS and 18F-fluoride PET/CT (conclusive, inconclusive, nonvisible) and lesions on each modality were correlated. The clinical course was followed to see if the results of 18F-fluoride PET/CT affected the decision of patient management.
Results
Sixty-one painful lesions in 31 patients included 16 forefoot (26.2 %), 11 midfoot (18.0 %), 19 hindfoot (31.2 %), 6 ankle (9.8 %), and 9 diffuse footpain (14.8 %). Forty lesions (40/61, 65.6 %) were detected on DBS, including 21 conclusive diagnostic (21/40, 52.5 %), mainly including hindfoot lesions (n = 11). The inconclusive 19 lesions (19/40, 47.5 %) on DBS showed conclusive diagnostic findings on 18F-fluoride PET/CT, mainly in fore and midfoot lesions (n = 15). Twenty-one painful lesions (21/61, 34.4 %) which were nonvisible on DBS revealed conclusive diagnostic findings on 18F-fluoride PET/CT in 7 lesions (7/21, 33.3 %), including 5 hindfoot lesions. Fourteen nonvisible lesions (14/21, 66.7 %) on both modalities included all 9 diffuse painful foot lesions. Patient management was affected by findings of 18F-fluoride PET/CT in 31 lesions (31/61, 50.8 %).
Conclusions
18F-fluoride PET/CT provided more confirmative diagnostic information in painful foot and ankle over DBS, and influenced patient management in many inconclusive or nonvisible cases on DBS. Increasing role of 18F-fluoride PET/CT in benign diseases including foot and ankle pain is expected in the near future.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mohan HK, Gnanasegaran G, Vijayanathan S, Fogelman I. SPECT/CT in imaging foot and ankle pathology—the demise of other coregistration techniques. Semin Nucl Med. 2010;40:41–51.
Nathan M, Mohan H, Vijayanathan S, Fogelman I, Gnanasegaran G. The role of 99mTc-diphosphonate bone SPECT/CT in the ankle and foot. Nucl Med Commun. 2012;33:799–807.
Groshar D, Gorenberg M, Ben-Haim S, Jerusalmi J, Liberson A. Lower extremity scintigraphy: the foot and ankle. Semin Nucl Med. 1998;28:62–77.
Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381–9.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.
Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32:168–76.
Kawaguchi M, Tateishi U, Shizukuishi K, Suzuki A, Inoue T. 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT. Ann Nucl Med. 2010;24:241–7.
Tateishi U, Morita S, Taguri M, Shizukuishi K, Minamimoto R, Kawaguchi M, et al. A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010;24:523–31.
Segall G, Delbeke D, Stabin MG, Even-Sapir E, Fair J, Sajdak R, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51:1813–20.
Pagenstert GI, Barg A, Leumann AG, Rasch H, Müller-Brand J, Hintermann B, et al. SPECT-CT imaging in degenerative joint disease of the foot and ankle. J Bone Joint Surg Br. 2009;91:1191–6.
Meftah M, Katchis SD, Scharf SC, Mintz DN, Klein DA, Weiner LS. SPECT/CT in the management of osteochondral lesions of the talus. Foot Ankle Int. 2011;32:233–8.
Mohan H, Holker P, Gnanasegaran G, Vijayanathan S, Sharp D, Langroudi B, et al. The applicability of SPECT-CT in directing the management of bony foot and ankle pathology. Eur J Nucl Med Mol Imaging. 2007;34(suppl 2):S166.
Gnanasegaran G, Mohan HK, Sharp D, Adamson K, Greig J, Vijayanathan S, et al. Single photon emission computed tomography-computed tomography in the management of foot pathology [Abstract]. Nucl Med Commun. 2008;29:482.
Fischer DR, Maquieira GJ, Espinosa N, Zanetti M, Hesselmann R, Johayem A, et al. Therapeutic impact of [18F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain. Skeletal Radiol. 2010;39:987–97.
Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR. Clinical utility of 18F-fluoride PET/CT in benign and malignant bone diseases. Bone. 2012;50:128–39.
Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med. 2010;51:1826–9.
Lawrence DA, Rolen MF, Morshed KA, Moukaddam H. MRI of heel pain. AJR Am J Roentgenol. 2013;200:845–55.
Foo LF, Raby N. Tumours and tumour-like lesions in the foot and ankle. Clin Radiol. 2005;60:308–32.
Acknowledgments
This work was supported by the research fund of Hanyang University (HY-2011-00000002285) and by Duchembio Co., Ltd., Seoul, Korea.
Conflict of interest
The authors have no potential conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, J.Y., Choi, Y.Y., Kim, Y.H. et al. Role of 18F-fluoride PET/CT over dual-phase bone scintigraphy in evaluation and management of lesions causing foot and ankle pain. Ann Nucl Med 29, 302–312 (2015). https://doi.org/10.1007/s12149-014-0942-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-014-0942-6